NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
03/24/2025
Back to search
Official data from USPTO
ZARXIO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
45
Latest update
04/16/2025
Trademark type
Word
Nice classes
5
Filing date
12/18/2012
Registration date
10/27/2015
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/24/2025
Last transaction
04/16/2025
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/03/2015
First use in commerce
09/03/2015
Drawing code
4
Owner type
03
Owner location
BASEL, CH
Examiner
FAIRBANKS, RONALD
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
SANDOZ AG
Novartis AG
Representatives
Maury M. Tepper, III TEPPER & EYSTER, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in stimulating white blood cell productionsold only by prescription
Publications
History of USPTO decisions and trademark events.
45 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
03/24/2025
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
03/24/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/24/2025
E89R
TEAS SECTION 8 & 9 RECEIVED
11/12/2024
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
10/28/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
12/06/2023
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
04/06/2021
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
04/06/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/06/2021
E815
TEAS SECTION 8 & 15 RECEIVED
12/21/2020
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
10/27/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
10/27/2015
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/22/2015
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/21/2015
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/14/2015
IUAF
USE AMENDMENT FILED
09/03/2015
EISU
TEAS STATEMENT OF USE RECEIVED
09/03/2015
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/16/2015
EX4G
SOU EXTENSION 4 GRANTED
07/15/2015
EXT4
SOU EXTENSION 4 FILED
07/01/2015
EEXT
SOU TEAS EXTENSION RECEIVED
07/01/2015
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/27/2015
EX3G
SOU EXTENSION 3 GRANTED
01/26/2015
EXT3
SOU EXTENSION 3 FILED
12/31/2014
EEXT
SOU TEAS EXTENSION RECEIVED
12/31/2014
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/31/2014
EX2G
SOU EXTENSION 2 GRANTED
07/30/2014
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/29/2014
EXT2
SOU EXTENSION 2 FILED
06/30/2014
EEXT
SOU TEAS EXTENSION RECEIVED
06/30/2014
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/01/2014
EX1G
SOU EXTENSION 1 GRANTED
12/29/2013
EXT1
SOU EXTENSION 1 FILED
12/29/2013
EEXT
SOU TEAS EXTENSION RECEIVED
12/29/2013
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/02/2013
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/07/2013
PUBO
PUBLISHED FOR OPPOSITION
05/07/2013
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/17/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
04/02/2013
ALIE
ASSIGNED TO LIE
04/02/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/30/2013
DOCK
ASSIGNED TO EXAMINER
03/30/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/07/2013
NWAP
NEW APPLICATION ENTERED
12/21/2012
Continuous trademark protection
Get notified about every new filing that threatens ZARXIO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.